Pharmafile Logo
Pharmafocus logo
Advanced Search

nephropathy

Showing 4 posts of 4 posts found.

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024
Research and Development Fabhalta, IgAN, Nephrology, Novartis, nephropathy

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN trial of Fabhalta (iptacopan), an …

News

Vertex to acquire Alpine Immune Sciences for $4.9bn

April 11, 2024
Business Services Alpine Immune Sciences, Nephrology, Vertex pharmaceuticals, acquisition, nephropathy

Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will …

News

Calliditas’ kidney disease drug granted priority review by FDA

April 28, 2021
Research and Development Calliditas, FDA, nephropathy, pharma, pharma news

The FDA has granted priority review for the New Drug Applicaton (NDA) for Calliditas Therapeutics’ Nefecon, for the treatment of …

News
AstraZeneca image

AZ and Mitsubishi partner on diabetic nephropathy

August 20, 2014
Research and Development, Sales and Marketing AstraZeneca, BMS, Mitsubishi, cvmd, diabetes, nephropathy

AstraZeneca and Japanese firm Mitsubishi Tanabe Pharma Corporation (MTPC) have signed a new three-year research deal in the area of …

News

Latest content

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024

PeptiDream and Novartis extend peptide discovery collaboration

April 30, 2024

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024